Edward Rosfjord

2.7k total citations · 1 hit paper
39 papers, 1.9k citations indexed

About

Edward Rosfjord is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Edward Rosfjord has authored 39 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 22 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Edward Rosfjord's work include HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cancer-related Molecular Pathways (5 papers). Edward Rosfjord is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cancer-related Molecular Pathways (5 papers). Edward Rosfjord collaborates with scholars based in United States, United Kingdom and Japan. Edward Rosfjord's co-authors include Robert B. Dickson, Sridhar K. Rabindran, Angie Rizzino, Judy Lucas, Yu‐Fen Wang, M. Brawner Floyd, Bernard D. Johnson, Hwei‐Ru Tsou, William Hallett and Marvin F. Reich and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

Edward Rosfjord

39 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

2004 503 citations Sridhar K. Rabindran, Edward Rosfjord et al. profile →

Peers

Countries citing papers authored by Edward Rosfjord

Since Specialization

Citations

This map shows the geographic impact of Edward Rosfjord's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Rosfjord with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Rosfjord more than expected).

Fields of papers citing papers by Edward Rosfjord

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Rosfjord. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Rosfjord. The network helps show where Edward Rosfjord may publish in the future.

Co-authorship network of co-authors of Edward Rosfjord

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Rosfjord. A scholar is included among the top collaborators of Edward Rosfjord based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Rosfjord. Edward Rosfjord is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P1.12-04 In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a Broad Panel of NSCLC Patient-Derived Xenograft Models 2023 ·Journal of Thoracic Oncology ·(unknown), Edward Rosfjord, S. Christ, Ying Zheng, Nicolas Floc’h, (unknown), (unknown), Sara Batelli, Edward Cantu, Sara Makaretz, (unknown), Fernanda I. Arnaldez, Frank I. Comer	2
2	Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody–Drug Conjugate Efficacy and Toxicity 2022 ·Molecular Cancer Therapeutics ·Arnaud Tiberghien, Balakumar Vijayakrishnan, (unknown), (unknown), (unknown), John P. Bingham, Lauren Adams, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ravinder Tammali, Edward Rosfjord, (unknown), John A. Hartley, Philip W. Howard	3
3	35MO Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers 2021 ·Annals of Oncology ·Étienne Dardenne, (unknown), (unknown), Shao Ning Yang, Ahmet Mentes, Luisa Shin Ogawa, (unknown), Anthony F. Trombino, Sherri Smith, Darlene Romashko, Noboru Ishiyama, (unknown), Shalabh Thakur, Edward Rosfjord, Elizabeth Buck, (unknown), Matthew C. Lucas, (unknown)	1
4	Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1 2020 ·Journal of Pharmacokinetics and Pharmacodynamics ·Alison Betts, Tracey Clark, Paul Jasper, John Tolsma, Piet H. van der Graaf, Edmund I. Graziani, Edward Rosfjord, Matthew Sung, Dangshe Ma, Frank Barletta	19
5	Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors 2020 ·BMC Genomics ·Wenyan Zhong, Jeremy S. Myers, Fang Wang, Kai Wang, Justin Lucas, Edward Rosfjord, Judy Lucas, Andrea T. Hooper, Sharon Yang, (unknown), Magali Guffroy, Chad May, Jadwiga Biénkowska, Paul A. Rejto	113
6	Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1) 2017 ·Molecular Cancer Therapeutics ·Matthew Sung, Xingzhi Tan, Bingwen Lu, Jonathan Golas, Christine Hosselet, Fang Wang, Laurie Tylaska, Lindsay King, Dahui Zhou, Russell G. Dushin, Jeremy S. Myers, Edward Rosfjord, Judy Lucas, Hans‐Peter Gerber, Frank Loganzo	155
7	Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes 2015 ·Clinical Cancer Research ·Boris Shor, Jennifer Kahler, Maureen Dougher, (unknown), Michelle Mack, Edward Rosfjord, Fang Wang, Eugene Melamud, Puja Sapra	21
8	Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology 2014 ·Biochemical Pharmacology ·Edward Rosfjord, Judy Lucas, Gang Li, Hans‐Peter Gerber	123
9	p120 catenin is a key effector of a Ras-PKCɛ oncogenic signaling axis 2013 ·Oncogene ·Stephen G. Dann, Jonathon Golas, Miriam Miranda, (unknown), Jieling Wu, Guofeng Jin, Edward Rosfjord, Erik Upeslacis, Anke Klippel	25
10	The interaction of PKN3 with RhoC promotes malignant growth 2011 ·Molecular Oncology ·Keziban Ünsal-Kaçmaz, (unknown), Edward Rosfjord, Stephen G. Dann, Erik Upeslacis, Mary Grillo, Richard Hernandez, Fiona Mack, Anke Klippel	39
11	2-Aryl-4,5,6,7-tetrahydro-1,3-benzothiazol-7-ols as a class of antitumor agents selectively active in securin−/− cells 2010 ·Bioorganic & Medicinal Chemistry Letters ·Nan Zhang, Semiramis Ayral‐Kaloustian, (unknown), Thai Nguyen, Erik Upeslacis, Tarek S. Mansour, (unknown), Edward Rosfjord	1
12	Control of mammary tumor differentiation by SKI-606 (bosutinib) 2010 ·Oncogene ·Lionel Hebbard, (unknown), Jonathon Golas, Junko Sawada, Lesley G. Ellies, (unknown), Roy Williams, (unknown), Miriam Wankell, Kim Arndt, Susan Quinn DeJoy, Robert A. Rollins, Veronica Diesl, Maximillian T. Follettie, Li-Mei Chen, Edward Rosfjord, Robert D. Cardiff, Masanobu Komatsu, Frank Boschelli, Robert G. Oshima	25
13	Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression 2005 ·Breast Cancer Research and Treatment ·Mary Grillo, Matthew J. Bott, (unknown), John P. McGinnis, Miriam Miranda, (unknown), Edward Rosfjord, Sridhar K. Rabindran	73
14	Application of Flow Cytometry in the Analysis and Sterile Sorting of Cell Populations Based on Integrin Expression 2003 ·Humana Press eBooks ·Edward Rosfjord, Robert B. Dickson	1
15	Growth Factors, Apoptosis, and Survival of Mammary Epithelial Cells 1999 ·Journal of Mammary Gland Biology and Neoplasia ·Edward Rosfjord, Robert B. Dickson	80
16	Appearance of Nuclear Protease Activity after Embryonal Carcinoma Cells Undergo Differentiation 1996 ·Developmental Biology ·Beáta Scholtz, (unknown), Edward Rosfjord, (unknown), Angie Rizzino	33
17	Binding of transcription factors to widely-separated cis-regulatory elements of the murine FGF-4 gene 1996 ·Molecular Reproduction and Development ·(unknown), Edward Rosfjord, (unknown), Angie Rizzino	18
18	Cryptic promoter activity within the backbone of a plasmid commonly used to prepare promoter/reporter gene constructs 1994 ·In Vitro Cellular & Developmental Biology - Animal ·Edward Rosfjord, (unknown), Angie Rizzino	26
19	The Octamer Motif Present in the Rex-1 Promoter Binds Oct-1 and Oct-3 Expressed by EC Cells and ES Cells 1994 ·Biochemical and Biophysical Research Communications ·Edward Rosfjord, Angie Rizzino	31
20	Transcriptional regulation of the murine k‐fgf gene 1994 ·Molecular Reproduction and Development ·Angie Rizzino, Edward Rosfjord	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact